市場調査レポート
商品コード
1562250

アジア太平洋の感染症治療薬：2030年市場予測- 地域別分析- 薬剤クラス別、適応症別、投与経路別、流通チャネル別

Asia Pacific Infectious Disease Therapeutics Market Forecast to 2030 - Regional Analysis - by Drug Class, Indication, Route Of Administration, and Distribution Channel
表紙：アジア太平洋の感染症治療薬：2030年市場予測- 地域別分析- 薬剤クラス別、適応症別、投与経路別、流通チャネル別

出版日
ページ情報
英文 101 Pages
納期
即納可能
アジア太平洋の感染症治療薬：2030年市場予測- 地域別分析- 薬剤クラス別、適応症別、投与経路別、流通チャネル別
出版日: 2024年07月04日
発行: The Insight Partners
ページ情報: 英文 101 Pages
納期: 即納可能
GIIご利用のメリット

  • 全表示

  • 概要
  • 図表
  • 目次
概要

アジア太平洋の感染症治療薬市場は、2022年に259億461万米ドルと評価され、2030年には374億1,507万米ドルに達すると予測され、2022年から2030年までのCAGRは4.7%と推定されます。

新興国市場での機会拡大がアジア太平洋の感染症治療薬市場を押し上げる

感染症の罹患率の増加により、新興諸国における感染症治療薬の売上が増加すると予測されます。アジア太平洋地域は、データ要件が緩やかで規制が厳しいため、適応しやすくビジネスに適した拠点となっています。加えて、新興諸国における健康研究とライフサイエンスへの高い投資は、発展途上国における最新技術の促進に重要な役割を果たしており、ひいては感染症診断・治療への傾倒を支えています。例えば、米国エイズ庁（UNAIDS）は、エイズ対策における低・中所得国のニーズを満たすため、2025年までに290億米ドルの投資を呼びかけています。したがって、インドや韓国の新興感染症治療薬市場における重要な感染症治療薬メーカーには、将来的に有利なビジネスチャンスが到来すると予想されます。その背景には、肝炎、HAI、HIV、インフルエンザなどの感染症が蔓延していること、患者数が多いこと、国民の可処分所得が増加していること、医療インフラが改善されていること、医療ツーリズムが増加していることなどがあります。

アジア太平洋の感染症治療薬市場概要

アジア太平洋の感染症治療薬市場は、中国、インド、日本、韓国、オーストラリア、その他アジア太平洋地域に細分化されます。アジア太平洋地域は、予測期間中に最も速いCAGRを記録すると予想されます。同地域の市場は、世界のヘルスケア支出の増加、慢性疾患や感染症の罹患率の増加、高齢者人口の増加に起因して成長すると予想されます。中国ではインフルエンザ、B型肝炎、感染性下痢などの感染症が、インドでは腸チフス、マラリア、黄疸、結核、エイズなどが一般的です。インフルエンザ、B型肝炎、感染性下痢症は中国でよく見られる3つの感染症です。Frontiers Public Healthが述べているように、インフルエンザの冬のピークは、2021年に同国でCOVID-19が発生した時期と重なります。世界銀行の2020年中国担当ディレクターによると、同国は人口の増加、野生動物の多さ、生息地の分断化、家畜生産量の多さなどから、感染症のリスクが高いとのことです。世界銀行理事会は、同国の感染症発生率の増加を考慮し、新興感染症予防・準備・対応プロジェクトに対する3億米ドルの融資を承認しました。これにより、人獣共通感染症やその他の新興の健康脅威のリスクを軽減することができます。このように、感染症の罹患率の上昇と、これらの病気を制御するために取られた措置は、今後数年間で中国の感染症治療薬市場を押し上げると予想されます。

アジア太平洋の感染症治療薬市場の収益と2030年までの予測（金額）

アジア太平洋の感染症治療薬市場のセグメンテーション

アジア太平洋の感染症治療薬市場は、薬剤クラス別、適応症別、投与経路別、流通チャネル別、国別に分類されます。

薬剤クラス別では、アジア太平洋の感染症治療薬市場は抗ウイルス薬、抗細菌薬、抗真菌薬、その他に区分されます。2022年の市場シェアは抗ウイルス剤が最大でした。

適応症の観点から、アジア太平洋の感染症治療薬市場はHIV、肝炎、結核、インフルエンザ、HPV、その他に区分されます。2022年にはHIVが最大の市場シェアを占めています。

投与経路に基づき、アジア太平洋の感染症治療薬市場は経口剤、非経口剤、局所剤、その他に区分されます。2022年の市場シェアは経口剤が最大でした。

流通チャネルでは、アジア太平洋の感染症治療薬市場は病院薬局、小売薬局、その他に区分されます。病院薬局が2022年に最大の市場シェアを占めました。

国別では、アジア太平洋の感染症治療薬市場は中国、日本、インド、オーストラリア、韓国、その他アジア太平洋地域に区分されます。2022年のアジア太平洋の感染症治療薬市場シェアは中国が独占しました。

AbbVie Inc、Astellas Pharma Inc、Bayer AG、F. Hoffmann-La Roche Ltd、Gilead Sciences Inc、GSK Plc、Merck &Co Inc、Pfizer Inc、Shionogi &Co Ltdは、アジア太平洋の感染症治療薬市場で事業を展開する主要企業の一部です。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

  • 主要な洞察

第3章 調査手法

  • 調査範囲
  • 2次調査
  • 1次調査

第4章 アジア太平洋の感染症治療薬市場- 主な市場力学

  • アジア太平洋の感染症治療薬市場- 主な市場ダイナミクス
  • 市場促進要因
    • 感染症の有病率の上昇
    • 感染症治療薬の資金調達と研究開発への注目の高まり
  • 市場抑制要因
    • 抗感染症薬の耐性とそれに伴う副作用の出現
  • 市場機会
    • 発展途上国における成長機会
    • 抗生物質耐性の脅威の高まり
  • 今後の動向
    • 承認・上市数の増加
  • 促進要因と抑制要因の影響

第5章 感染症治療薬市場-アジア太平洋市場分析

  • アジア太平洋の感染症治療薬市場収益、2022年～2030年

第6章 アジア太平洋の感染症治療薬市場分析：薬剤クラス別

  • 抗ウイルス剤
  • 抗細菌薬
  • 抗真菌薬
  • その他

第7章 アジア太平洋の感染症治療薬市場分析：適応症別

  • HIV
  • 肝炎
  • 結核
  • インフルエンザ
  • HPV
  • その他

第8章 アジア太平洋の感染症治療薬市場分析：投与経路別

  • 経口
  • 非経口
  • 局所
  • その他

第9章 アジア太平洋の感染症治療薬市場分析：流通チャネル別

  • 病院薬局
  • 小売薬局
  • その他

第10章 アジア太平洋の感染症治療薬市場：国別分析

  • 中国
  • 日本
  • インド
  • オーストラリア
  • 韓国
  • その他アジア太平洋地域

第11章 感染症治療薬市場-業界情勢

  • 感染症治療薬市場における成長戦略
  • 無機的成長戦略
  • 有機的成長戦略

第12章 企業プロファイル

  • Pfizer Inc
  • Gilead Sciences Inc
  • F. Hoffmann-La Roche Ltd
  • Shionogi & Co Ltd
  • Bayer AG
  • GSK Plc
  • AbbVie Inc
  • Merck & Co Inc
  • Astellas Pharma Inc

第13章 付録

図表

List Of Tables

  • Table 1. Asia Pacific Infectious Disease Therapeutics Market Segmentation
  • Table 2. Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Drug Class
  • Table 3. Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Indication
  • Table 4. Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Route of Administration
  • Table 5. Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Distribution Channel
  • Table 6. Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Country
  • Table 7. China: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class
  • Table 8. China: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication
  • Table 9. China: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
  • Table 10. China: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
  • Table 11. Japan: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class
  • Table 12. Japan: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication
  • Table 13. Japan: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
  • Table 14. Japan: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
  • Table 15. India: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class
  • Table 16. India: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication
  • Table 17. India: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route Of Administration
  • Table 18. India: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
  • Table 19. Australia: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class
  • Table 20. Australia: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication
  • Table 21. Australia: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route Of Administration
  • Table 22. Australia: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
  • Table 23. South Korea: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class
  • Table 24. South Korea: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication
  • Table 25. South Korea: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
  • Table 26. South Korea: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
  • Table 27. Rest of Asia Pacific: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class
  • Table 28. Rest of Asia Pacific: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication
  • Table 29. Rest of Asia Pacific: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
  • Table 30. Rest of Asia Pacific: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
  • Table 31. Recent Inorganic Growth Strategies in the Infectious Disease Therapeutics Market
  • Table 32. Recent Organic Growth Strategies in the Infectious Disease Therapeutics Market

List Of Figures

  • Figure 1. Asia Pacific Infectious Disease Therapeutics Market Segmentation, by Country
  • Figure 2. Impact Analysis of Drivers and Restraints
  • Figure 3. Asia Pacific Infectious Disease Therapeutics Market Revenue (US$ Million), 2022-2030
  • Figure 4. Asia Pacific Infectious Disease Therapeutics Market Share (%) - by Drug Class (2022 and 2030)
  • Figure 5. Anti-viral: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 6. Anti-bacterial: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 7. Anti-fungal: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 8. Others: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 9. Asia Pacific Infectious Disease Therapeutics Market Share (%) - by Indication (2022 and 2030)
  • Figure 10. HIV: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 11. Hepatitis: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 12. Tuberculosis: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 13. Influenza: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 14. HPV: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 15. Others: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 16. Asia Pacific Infectious Disease Therapeutics Market Share (%) - by Route Of Administration (2022 and 2030)
  • Figure 17. Oral: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 18. Parenteral: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 19. Topical: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 20. Others: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 21. Asia Pacific Infectious Disease Therapeutics Market Share (%) - by Distribution Channel (2022 and 2030)
  • Figure 22. Hospital Pharmacies: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 23. Retail Pharmacies: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 24. Others: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 25. Asia Pacific Infectious Disease Therapeutics Market, by Key Country - Revenue (2022) (US$ Million)
  • Figure 26. Asia Pacific Infectious Disease Therapeutics Market Breakdown, by Key Countries, 2022 and 2030 (%)
  • Figure 27. China: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 28. Japan: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 29. India: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 30. Australia: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 31. South Korea: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 32. Rest of Asia Pacific: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 33. Growth Strategies in the Infectious Disease Therapeutics Market
目次
Product Code: BMIRE00030366

The Asia Pacific infectious disease therapeutics market was valued at US$ 25,904.61 million in 2022 and is expected to reach US$ 37,415.07 million by 2030; it is estimated to register a CAGR of 4.7% from 2022 to 2030.

Growing Opportunities in Developing Nations Boost Asia Pacific Infectious Disease Therapeutics Market

The growing incidence of infectious diseases is anticipated to increase the sales of infectious disease therapeutics drugs in developing countries. Asia Pacific has become an adaptable and business-friendly hub due to moderately fewer data requirements and stringent regulations. In addition, high investments in health research and life science in emerging countries play a key role in promoting the latest technologies in developing countries, which, in turn, supports the inclination toward infectious disease diagnosis and treatment. For instance, UNAIDS is calling for an investment of US$ 29 billion by 2025 to meet the needs of low- and middle-income countries in the AIDS response. Thus, crucial infectious disease therapeutics product manufacturers in emerging infectious disease therapeutics markets in India and South Korea, are expected to witness lucrative opportunities in the future. This is owing to the high prevalence of infectious diseases such as Hepatitis, HAI, HIV, and influenza; a large population of patients; a rise in disposable income of the population; improving infrastructure of healthcare; and growing medical tourism in these countries.

Asia Pacific Infectious Disease Therapeutics Market Overview

The Asia Pacific infectious disease therapeutics market is sub-segmented into China, India, Japan, South Korea, Australia, and the Rest of Asia Pacific. Asia Pacific is expected to register the fastest CAGR during the forecast period. The market in the region is expected to grow owing to rising global healthcare expenditure, increasing incidence of chronic and infectious diseases, and a growing geriatric population base. The infectious disease such as influenza, hepatitis B, and infectious diarrhea are common in China and typhoid, malaria, jaundice, tuberculosis, and AIDS in India. Influenza, hepatitis B, and infectious diarrhea are the three common infectious diseases in China. As stated by Frontiers Public Health, the winter peak of influenza coincided with the outbreak of COVID-19 in the country in 2021. According to the World Bank Country Director of China 2020, the country is at a high risk of infectious diseases due to its growing population, wildlife abundance, habitat fragmentation, and high livestock production levels. Considering the country's growing incidence of infectious diseases, the World Bank's Board of Executive Directors approved a US$ 300 million loan for the Emerging Infectious Diseases Prevention, Preparedness and Response Project. This will help it reduce the risk of zoonotic and other emerging health threats. Thus, the rising incidence of infectious diseases and measures taken to control these diseases are expected to boost the China infectious disease therapeutics market in the coming years.

Asia Pacific Infectious Disease Therapeutics Market Revenue and Forecast to 2030 (US$ Million)

Asia Pacific Infectious Disease Therapeutics Market Segmentation

The Asia Pacific infectious disease therapeutics market is categorized into drug class, indication, route of administration, distribution channel, and country.

Based on drug class, the Asia Pacific infectious disease therapeutics market is segmented into anti-viral, anti-bacterial, anti-fungal, and others. The anti-viral segment held the largest market share in 2022.

In terms of indication, the Asia Pacific infectious disease therapeutics market is segmented into HIV, hepatitis, tuberculosis, influenza, HPV, and others. The HIV held the largest market share in 2022.

Based on route of administration, the Asia Pacific infectious disease therapeutics market is segmented into oral, parenteral, topical, and others. The oral segment held the largest market share in 2022.

In terms of distribution channel, the Asia Pacific infectious disease therapeutics market is segmented into hospital pharmacies, retail pharmacies, and others. The hospital pharmacies held the largest market share in 2022.

By country, the Asia Pacific infectious disease therapeutics market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific infectious disease therapeutics market share in 2022.

AbbVie Inc, Astellas Pharma Inc, Bayer AG, F. Hoffmann-La Roche Ltd, Gilead Sciences Inc, GSK Plc , Merck & Co Inc, Pfizer Inc, and Shionogi & Co Ltd are some of the leading companies operating in the Asia Pacific infectious disease therapeutics market.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. Asia Pacific Infectious Disease Therapeutics Market - Key Market Dynamics

  • 4.1 Asia Pacific Infectious Disease Therapeutics Market - Key Market Dynamics
  • 4.2 Market Drivers
    • 4.2.1 Rising Prevalence of Infectious Disease
    • 4.2.2 Increasing Focus on Funding and R&D in Infectious Disease Therapeutics
  • 4.3 Market Restraints
    • 4.3.1 Emergence of Anti-infective Drugs Resistance and Associated Side Effects
  • 4.4 Market Opportunities
    • 4.4.1 Growing Opportunities in Developing Nations
    • 4.4.2 Escalating Threat of Antibiotic Resistance
  • 4.5 Future Trends
    • 4.5.1 Rising Number of Product Approvals and Launches
  • 4.6 Impact of Drivers and Restraints:

5. Infectious Disease Therapeutics Market - Asia Pacific Market Analysis

  • 5.1 Asia Pacific Infectious Disease Therapeutics Market Revenue (US$ Million), 2022-2030

6. Asia Pacific Infectious Disease Therapeutics Market Analysis - by Drug Class

  • 6.1 Overview
  • 6.2 Anti-Viral
    • 6.2.1 Overview
    • 6.2.2 Anti-viral: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 6.3 Anti-bacterial
    • 6.3.1 Overview
    • 6.3.2 Anti-bacterial: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 6.4 Anti-fungal
    • 6.4.1 Overview
    • 6.4.2 Anti-fungal: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 6.5 Others
    • 6.5.1 Overview
    • 6.5.2 Others: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

7. Asia Pacific Infectious Disease Therapeutics Market Analysis - by Indication

  • 7.1 Overview
  • 7.2 HIV
    • 7.2.1 Overview
    • 7.2.2 HIV: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.3 Hepatitis
    • 7.3.1 Overview
    • 7.3.2 Hepatitis: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.4 Tuberculosis
    • 7.4.1 Overview
    • 7.4.2 Tuberculosis: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.5 Influenza
    • 7.5.1 Overview
    • 7.5.2 Influenza: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.6 HPV
    • 7.6.1 Overview
    • 7.6.2 HPV: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.7 Others
    • 7.7.1 Overview
    • 7.7.2 Others: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

8. Asia Pacific Infectious Disease Therapeutics Market Analysis - by Route of Administration

  • 8.1 Overview
  • 8.2 Oral
    • 8.2.1 Overview
    • 8.2.2 Oral: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.3 Parenteral
    • 8.3.1 Overview
    • 8.3.2 Parenteral: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.4 Topical
    • 8.4.1 Overview
    • 8.4.2 Topical: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.5 Others
    • 8.5.1 Overview
    • 8.5.2 Others: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

9. Asia Pacific Infectious Disease Therapeutics Market Analysis - by Distribution Channel

  • 9.1 Overview
  • 9.2 Hospital Pharmacies
    • 9.2.1 Overview
    • 9.2.2 Hospital Pharmacies: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 9.3 Retail Pharmacies
    • 9.3.1 Overview
    • 9.3.2 Retail Pharmacies: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 9.4 Others
    • 9.4.1 Overview
    • 9.4.2 Others: Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

10. Asia Pacific Infectious Disease Therapeutics Market - Country Analysis

  • 10.1 Asia Pacific Infectious Disease Therapeutics Market Overview
    • 10.1.1 Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast Analysis - by Country
      • 10.1.1.1 Asia Pacific Infectious Disease Therapeutics Market - Revenue and Forecast Analysis - by Country
      • 10.1.1.2 China: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.2.1 Overview
      • 10.1.1.3 China: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.3.1 China: Infectious Disease Therapeutics Market Breakdown, by Drug Class
        • 10.1.1.3.2 China: Infectious Disease Therapeutics Market Breakdown, by Indication
        • 10.1.1.3.3 China: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
        • 10.1.1.3.4 China: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
      • 10.1.1.4 Japan: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.4.1 Overview
      • 10.1.1.5 Japan: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.5.1 Japan: Infectious Disease Therapeutics Market Breakdown, by Drug Class
        • 10.1.1.5.2 Japan: Infectious Disease Therapeutics Market Breakdown, by Indication
        • 10.1.1.5.3 Japan: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
        • 10.1.1.5.4 Japan: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
      • 10.1.1.6 India: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.6.1 Overview
      • 10.1.1.7 India: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.7.1 India: Infectious Disease Therapeutics Market Breakdown, by Drug Class
        • 10.1.1.7.2 India: Infectious Disease Therapeutics Market Breakdown, by Indication
        • 10.1.1.7.3 India: Infectious Disease Therapeutics Market Breakdown, by Route Of Administration
        • 10.1.1.7.4 India: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
      • 10.1.1.8 Australia: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.8.1 Overview
      • 10.1.1.9 Australia: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.9.1 Australia: Infectious Disease Therapeutics Market Breakdown, by Drug Class
        • 10.1.1.9.2 Australia: Infectious Disease Therapeutics Market Breakdown, by Indication
        • 10.1.1.9.3 Australia: Infectious Disease Therapeutics Market Breakdown, by Route Of Administration
        • 10.1.1.9.4 Australia: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
      • 10.1.1.10 South Korea: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.10.1 Overview
      • 10.1.1.11 South Korea: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.11.1 South Korea: Infectious Disease Therapeutics Market Breakdown, by Drug Class
        • 10.1.1.11.2 South Korea: Infectious Disease Therapeutics Market Breakdown, by Indication
        • 10.1.1.11.3 South Korea: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
        • 10.1.1.11.4 South Korea: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
      • 10.1.1.12 Rest of Asia Pacific: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.12.1 Overview
      • 10.1.1.13 Rest of Asia Pacific: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.13.1 Rest of Asia Pacific: Infectious Disease Therapeutics Market Breakdown, by Drug Class
        • 10.1.1.13.2 Rest of Asia Pacific: Infectious Disease Therapeutics Market Breakdown, by Indication
        • 10.1.1.13.3 Rest of Asia Pacific: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
        • 10.1.1.13.4 Rest of Asia Pacific: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel

11. Infectious Disease Therapeutics Market-Industry Landscape

  • 11.1 Overview
  • 11.2 Growth Strategies in the Infectious Disease Therapeutics Market
  • 11.3 Inorganic Growth Strategies
    • 11.3.1 Overview
  • 11.4 Organic Growth Strategies
    • 11.4.1 Overview

12. Company Profiles

  • 12.1 Pfizer Inc
    • 12.1.1 Key Facts
    • 12.1.2 Business Description
    • 12.1.3 Products and Services
    • 12.1.4 Financial Overview
    • 12.1.5 SWOT Analysis
    • 12.1.6 Key Developments
  • 12.2 Gilead Sciences Inc
    • 12.2.1 Key Facts
    • 12.2.2 Business Description
    • 12.2.3 Products and Services
    • 12.2.4 Financial Overview
    • 12.2.5 SWOT Analysis
    • 12.2.6 Key Developments
  • 12.3 F. Hoffmann-La Roche Ltd
    • 12.3.1 Key Facts
    • 12.3.2 Business Description
    • 12.3.3 Products and Services
    • 12.3.4 Financial Overview
    • 12.3.5 SWOT Analysis
    • 12.3.6 Key Developments
  • 12.4 Shionogi & Co Ltd
    • 12.4.1 Key Facts
    • 12.4.2 Business Description
    • 12.4.3 Products and Services
    • 12.4.4 Financial Overview
    • 12.4.5 SWOT Analysis
    • 12.4.6 Key Developments
  • 12.5 Bayer AG
    • 12.5.1 Key Facts
    • 12.5.2 Business Description
    • 12.5.3 Products and Services
    • 12.5.4 Financial Overview
    • 12.5.5 SWOT Analysis
    • 12.5.6 Key Developments
  • 12.6 GSK Plc
    • 12.6.1 Key Facts
    • 12.6.2 Business Description
    • 12.6.3 Products and Services
    • 12.6.4 Financial Overview
    • 12.6.5 SWOT Analysis
    • 12.6.6 Key Developments
  • 12.7 AbbVie Inc
    • 12.7.1 Key Facts
    • 12.7.2 Business Description
    • 12.7.3 Products and Services
    • 12.7.4 Financial Overview
    • 12.7.5 SWOT Analysis
    • 12.7.6 Key Developments
  • 12.8 Merck & Co Inc
    • 12.8.1 Key Facts
    • 12.8.2 Business Description
    • 12.8.3 Products and Services
    • 12.8.4 Financial Overview
    • 12.8.5 SWOT Analysis
    • 12.8.6 Key Developments
  • 12.9 Astellas Pharma Inc
    • 12.9.1 Key Facts
    • 12.9.2 Business Description
    • 12.9.3 Products and Services
    • 12.9.4 Financial Overview
    • 12.9.5 SWOT Analysis
    • 12.9.6 Key Developments

13. Appendix

  • 13.1 About The Insight Partners